Cooksey R C, Morlock G P, McQueen A, Glickman S E, Crawford J T
National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
Antimicrob Agents Chemother. 1996 May;40(5):1186-8. doi: 10.1128/AAC.40.5.1186.
From a collection of 367 isolates of Mycobacterium tuberculosis from patients in New York City in 1994, 45 isolates (12.3%) were resistant in vitro to 2 micrograms or more of streptomycin (SM) per ml. We further evaluated these isolates for levels of SM resistance and for mutations previously associated with resistance in the rpsL (S12 ribosomal protein) gene and the rrs (16S rRNA)-coding region. Twenty-four isolates, representing nine distinct patterns of susceptibility to antituberculosis drugs, were resistant to 500 micrograms of SM per ml and shared a common point mutation at nucleotide 128 in the rpsL gene. This mutation, which substitutes lysine for arginine in the S12 ribosomal binding protein, was not present in isolates with low-level SM resistance or in SM-susceptible control isolates. Among 20 isolates with low-level SM resistance, one possessed a substitution (C-->G865) in the 912 loop of the rrs gene. No mutations in the 530 loop of the rrs coding region were detected, suggesting the presence of an alternative SM resistance mechanism in 19 isolates. Single-strand conformation polymorphisms of mutants were readily detected by a nonradioactive gel screen.
从1994年纽约市患者的367株结核分枝杆菌分离株中,有45株(12.3%)在体外对每毫升2微克或更多的链霉素(SM)耐药。我们进一步评估了这些分离株的链霉素耐药水平以及先前与rpsL(S12核糖体蛋白)基因和rrs(16S rRNA)编码区耐药相关的突变。24株分离株代表了9种不同的抗结核药物敏感性模式,对每毫升500微克链霉素耐药,并且在rpsL基因的第128位核苷酸处有一个共同的点突变。这种突变在S12核糖体结合蛋白中用赖氨酸替代精氨酸,在低水平链霉素耐药的分离株或链霉素敏感的对照分离株中不存在。在20株低水平链霉素耐药的分离株中,有一株在rrs基因的912环中有一个替代(C→G865)。在rrs编码区的530环中未检测到突变,提示19株分离株中存在另一种链霉素耐药机制。通过非放射性凝胶筛选很容易检测到突变体的单链构象多态性。